# The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

> **NCT04233346** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Otsuka Beijing Research Institute** · enrollment: 93 (actual)

## Conditions studied

- Chronic Myeloid Leukemia
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Ponatinib 30mg OD
- **DRUG:** Ponatinib 45mg OD

## Key facts

- **NCT ID:** NCT04233346
- **Lead sponsor:** Otsuka Beijing Research Institute
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-09
- **Primary completion:** 2022-07-22
- **Final completion:** 2025-12-31
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233346, "The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04233346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*